The abstract is read at the publisher; the summary is JClub's.
In 393 ADNI participants, plasma assays for pTau217 show strong agreement on biomarker levels (intraclass correlation 0.75–0.95) but only moderate reliability for individual rates of change (0.44, 95% CI 0.37–0.50).
- Why it matters: Serial plasma monitoring is proposed for tracking Alzheimer’s progression and for clinical trials, but it is unclear whether repeated assays can reliably estimate a person’s longitudinal change.
- What they did: Five biomarkers were measured 15 ways across aliquots from the same three plasma samples collected over a median 5.0 years, separating shared change from assay-specific variation; results were tested in 1,093 A4/LEARN participants.
- The result: Assay-specific slope variance was ~0, implying disagreement is mostly random; three-sample single-assay slope reliability was at most 0.40 for pTau217 and 0.10 for Aβ42/40, and detecting 25% slowing of pTau217 required 924–4,030 participants per arm.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.